Engineered exosomes for co‐delivery of PGM5‐AS1 and oxaliplatin to reverse drug resistance in colon cancer

Hui, Bingqing; Chen, Lu; Wang, Jing; Xu, Yetao; Yang, Yuchen; Ji, Hao; Li, Xiaofei; Xu, Lingyan; Wang, Jiawei; Tang, Weiwei; Wang, Ke‐Ming; Gu, Yue

doi:10.1002/jcp.30566

Cited by 52 publications

(32 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intriguingly, coencapsulation of oxaliplatin and PGM5AS1 in exosomes could efficiently reverse oxaliplatin resistance in CRCs. [ 280 ] CircRNA FBXW7 (circ‐FBXW7) is downregulated in oxaliplatin‐resistant CRC patients. Exosome‐mediated delivery of circ‐FBXW7 binds to miR‐128‐3p to induce CRC sensitivity to oxaliplatin and inhibit oxaliplatin outflow, which provides a promising strategy for treating oxaliplatin‐resistant CRC.…”

Section: The Potential Of Evs In Overcoming Cancer Drug Resistancementioning

confidence: 99%

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Yang

et al. 2022

Advanced Science

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are cell-derived nanosized vesicles that mediate cell-to-cell communication via transporting bioactive molecules and thus are critically involved in various physiological and pathological conditions. EVs contribute to different aspects of cancer progression, such as cancer growth, angiogenesis, metastasis, immune evasion, and drug resistance. EVs induce the resistance of cancer cells to chemotherapy, radiotherapy, targeted therapy, antiangiogenesis therapy, and immunotherapy by transferring specific cargos that affect drug efflux and regulate signaling pathways associated with epithelial-mesenchymal transition, autophagy, metabolism, and cancer stemness. In addition, EVs modulate the reciprocal interaction between cancer cells and noncancer cells in the tumor microenvironment (TME) to develop therapy resistance. EVs are detectable in many biofluids of cancer patients, and thus are regarded as novel biomarkers for monitoring therapy response and predicting prognosis. Moreover, EVs are suggested as promising targets and engineered as nanovehicles to deliver drugs for overcoming drug resistance in cancer therapy. In this review, the biological roles of EVs and their mechanisms of action in cancer drug resistance are summarized. The preclinical studies on using EVs in monitoring and overcoming cancer drug resistance are also discussed.

show abstract

Section: The Potential Of Evs In Overcoming Cancer Drug Resistancementioning

confidence: 99%

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Yang

et al. 2022

Advanced Science

View full text Add to dashboard Cite

show abstract

“…designed a versatile EV-based chemo/gene/photothermal therapy plantform for the next-generation precision cancer nanomedicines (Wang et al., 2021 ). Engineered EVs encapsulating PGM5 antisense RNA 1 and oxaliplatin can reverse drug resistance in colon cancer (Hui et al., 2021 ).…”

Section: Functionalized Evs For Cancer Therapymentioning

confidence: 99%

Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy

et al. 2022

View full text Add to dashboard Cite

Increasing evidences show that unmodified extracellular vesicles (EVs) derived from various cells can effectively inhibit the malignant progression of different types of tumors by delivering the bioactive molecules. Therefore, EVs are expected to be developed as emerging anticancer drugs. Meanwhile, unmodified EVs as an advanced and promising nanocarrier that is frequently used in targeted delivery therapeutic cargos and personalized reagents for the treatment and diagnosis of cancer. To improve the efficacy of EV-based treatments, researchers are trying to engineering EVs as an emerging nanomedicine translational therapy platform through biological, physical and chemical approaches, which can be broaden and altered to enhance their therapeutic capability. EVs loaded with therapeutic components such as tumor suppressor drugs, siRNAs, proteins, peptides, and conjugates exhibit significantly enhanced anti-tumor effects. Moreover, the design and preparation of tumor-targeted modified EVs greatly enhance the specificity and effectiveness of tumor therapy, and these strategies are expected to become novel ideas for tumor precision medicine. This review will focus on reviewing the latest research progress of functionalized EVs, clarifying the superior biological functions and powerful therapeutic potential of EVs, for researchers to explore new design concepts based on EVs and build next-generation nanomedicine therapeutic platforms.

show abstract

“…Recently, another lncRNA, PGM5-AS1 was found to reverse oxaliplatin resistance of CRC cells by acting as a sponge for miR-423-5p. More importantly, the authors suggested that combined delivery of PGM5-AS1 and oxaliplatin by engineered exosomes can reverse drug resistance [83].…”

Section: Exosomal Long Ncrnas and Crc Drug Resistancementioning

confidence: 99%

The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance

Lampropoulou

Pliakou

Aravantinos

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the most common types of cancer diagnosed worldwide with high morbidity; drug resistance is often responsible for treatment failure in CRC. Non-coding RNAs (ncRNAs) play distinct regulatory roles in tumorigenesis, cancer progression and chemoresistance. Methods: Α literature search was conducted in PubMed database in order to sum up and discuss the role of exosomal ncRNAs (ex-ncRNAs) in CRC drug resistance/response and their possible mechanisms. Results: Thirty-six (36) original research articles were identified; these included exosome or extracellular vesicle (EV)-containing microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and small-interfering (siRNAs). No studies were found for piwi-interacting RNAs. Conclusions: Exosomal transfer of ncRNAs has been documented as a new mechanism of CRC drug resistance. Despite being in its infancy, it has emerged as a promising field for research in order to (i) discover novel biomarkers for therapy monitoring and/or (ii) reverse drug desensitization.

show abstract

Engineered exosomes for co‐delivery of PGM5‐AS1 and oxaliplatin to reverse drug resistance in colon cancer

Cited by 52 publications

References 54 publications

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy

The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance

Contact Info

Product

Resources

About